Important Safety Information—Off-Target Effects of New Therapies for Diabetes
Friday, June 21, at 3:45 p.m. ET
Room W414
Orange County Convention Center
(Livestream Available)
Fixed-Ratio Insulin Combinations
Liana K. Billings, MD, MMSc
Endocrinologist/Clinical Associate Professor of Medicine,
NorthShore University HealthSystem/Endeavor Health
What is your presentation about?
The presentation will review the U.S. Food and Drug Administration-approved fixed-ratio insulin combinations, including IDegLira and IGlarLixi, and focus briefly on IcoSema currently in pre-approval trials. After a brief review of efficacy, we will examine the off-target effects including gastrointestinal (GI) side effects, hypoglycemia, weight gain, treatment burden, cost, and considerations in special populations. The presentation will illustrate how fixed-ratio combination basal insulin/glucagon-like peptide-1 (GLP-1) receptor agonist therapy can be an excellent choice for patients as they have lower rate of off-target effects than the mono-components with similar efficacy and less treatment burden. In this case, you can have your cake and eat it too!
How do you hope your presentation will impact diabetes research or care?
By the end of the presentation, attendees will understand that fixed-ratio basal insulin/GLP-1 receptor agonist therapy can be an advantageous therapy when efficacy is needed in the setting of fewer GI side effects, less hypoglycemia, and less weight gain.
How did you become involved with this area of diabetes research or care?
I became involved in this area of diabetes through initially research and then clinical care. I was fortunate to be a PI in the DUAL Phase 3 clinical trial program with IDegLira. I saw firsthand the reduced burden and fewer side effects in research volunteers taking IDegLira versus basal bolus therapy in the DUAL VII study. The findings of this study are remarkable with IDegLira showing similar A1C lowering, less weight gain, less hypoglycemia, and far fewer injections and glucose checks compared to basal-bolus. I now have had the opportunity to use fixed-ratio combination basal insulin/GLP-1 receptor agonist in the clinic and see how it has benefitted my patients in diabetes management and quality of life.